Platform Composition % EE* Particle Size [nm] Status Ref. Liposomes phosphatidylcholine, cholesterol, cardiolipin > 90 ~150 in-vitro [116] HSPC, cholesterol, PEG-DSPE ― ~100 in-vivo [117] phosphatidylglycerol, phosphatidylcholine ―  200, 900 in-vivo [118] Solid Lipid Nanoparticles tripalmitin, Epikuron 20, butanol, Na-taurocholate, cholesteryl hemisuccinate ― 160 in-vitro [121] stearic acid, lecithin, Brij 78 [or pluronic F68 and DSPE-PEG] 58-75 100-220 in-vivo [122] trimyristin, EPC, PEG2000-PE 72-89 200-250 in-vivo [123, 124] glyceryl palmitostearate [or glyceryl monostearate], poloxamer 407 55-90 ~200 in-vitro [127, 128] Lipoid S 100 sucrose fatty acid esters 89-92 150-190 in-vitro [129] stearylamine, soya lecithin, poloxamer 188 75 70-130 in-vivo [125] monostearin, stearic acid, glycerol tristearate, ATO 888 36-76 160-260 in-vitro [126] emulsifying wax, Brij 78 ~50 < 100 in-vivo [130, 131] glyceryl tridodecanoate, Brij 78 > 85 170 in-vitro [132, 133] Lipid Nanocapsules Labrafac®, Lipoïd® S75-3, Solutol® HS15 ― ~50 in-vivo [134-136] Captex® 8000, Lipoïd® S75-3, Solutol® HS15 93 ~50 in-vivo [137-140] Miglyol 812, Brij 78, TPGS 85-97 ~200 in-vivo [132, 133] PLGA, lecithin, DSPE-PEG2000, DSPC, RGD [targeting]   82 68 in-vivo [142, 143] Lipiodol, PEO-PPO-PEO, functionalized PEG, folic acid [targeting] 46 110 in-vivo [144] lecithin, Dynasan 118, Miglyol 812, folate-PEG-PE, Span 60 [or PEG-PE] 98 207 in-vivo [145] Micro- and Nano-Emulsions vitamin E, TPGS, poloxamer 407 ― 100 phase III/discontinued [154] oil blend, EPC, Tween 80, glycerol > 95 150 in-vivo [156] lecithin, butanol, myvacet [or capmul, myvacet] ― ~110 in-vivo [157, 158] pine nut oil, egg lecithin, stearylamine, deoxycholic acid ― 90-120 in-vivo [159] egg lecithin, flaxseed oil, DSPE-PEG2000 97-100 130-150 in-vitro [160]

Table 2: Summary of PX-loaded Lipid-based NPs. [*EE = Entrapment Efficiency].